Log in
NASDAQ:ATEC

Alphatec Competitors

$10.55
-0.25 (-2.31 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.43
Now: $10.55
$10.97
50-Day Range
$6.51
MA: $9.49
$10.80
52-Week Range
$2.19
Now: $10.55
$11.38
Volume861,230 shs
Average Volume660,956 shs
Market Capitalization$827.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Competitors

Alphatec (NASDAQ:ATEC) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ATEC stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Alphatec, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Abbott Laboratories and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Alphatec-51.95%-266.45%-40.80%

Analyst Ratings

This is a breakdown of current ratings for Abbott Laboratories and Alphatec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Alphatec00603.00

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Abbott Laboratories and Alphatec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68

Abbott Laboratories has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Alphatec on 9 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Medtronic and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Alphatec-51.95%-266.45%-40.80%

Analyst Ratings

This is a breakdown of current ratings for Medtronic and Alphatec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Alphatec00603.00

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Medtronic.

Valuation and Earnings

This table compares Medtronic and Alphatec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68

Medtronic has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Medtronic beats Alphatec on 10 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Stryker and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Alphatec-51.95%-266.45%-40.80%

Analyst Ratings

This is a breakdown of current ratings for Stryker and Alphatec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Alphatec00603.00

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Stryker.

Valuation and Earnings

This table compares Stryker and Alphatec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68

Stryker has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Stryker beats Alphatec on 10 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Intuitive Surgical and Alphatec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Alphatec00603.00

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Intuitive Surgical.

Institutional and Insider Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Intuitive Surgical and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Alphatec-51.95%-266.45%-40.80%

Volatility & Risk

Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and Alphatec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68

Intuitive Surgical has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Alphatec on 10 of the 14 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alphatec and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alphatec00603.00
Becton, Dickinson and07712.60

Alphatec presently has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Alphatec.

Institutional & Insider Ownership

31.3% of Alphatec shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alphatec-51.95%-266.45%-40.80%
Becton, Dickinson and5.11%13.30%5.60%

Risk and Volatility

Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alphatec and Becton, Dickinson and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Alphatec on 11 of the 15 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alphatec and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alphatec00603.00
Edwards Lifesciences251302.55

Alphatec presently has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Given Alphatec's stronger consensus rating and higher possible upside, analysts plainly believe Alphatec is more favorable than Edwards Lifesciences.

Institutional & Insider Ownership

31.3% of Alphatec shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alphatec-51.95%-266.45%-40.80%
Edwards Lifesciences18.18%29.00%18.10%

Risk and Volatility

Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alphatec and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$113.43 million7.29$-57,000,000.00($1.09)-9.68
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Alphatec on 10 of the 14 factors compared between the two stocks.


Alphatec Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27-1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97-0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01-0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05-1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48-1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70-0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33-1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79-1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77-1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09-1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57-0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89-0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07-1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14-0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09-3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50-0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50-1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43-0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55-0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47-1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78-0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98-0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32-2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18-2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37-2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24-1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90-1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
CryoLife logo
CRY
CryoLife
2.1$20.87-4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14-2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12-2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52-0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40-11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98-1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94-1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.